

Caribou Biosciences, Inc. (CRBU)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001619856

Caribou Biosciences, Inc.

CRBU; healthcare

Grade	D fourth fifth of 371 graded peers percentile 63.5; sampling error 2.5 points; lower is stronger
Rank	236 of 371
Profitability	B percentile 29.5
Solvency	C/D percentile 58.1
Growth and financing	D percentile 70.2
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$175.4M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	short runway not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 5, 2026 218 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026
Last close	\$0.48 2026-10-08; market equity \$51.6M
Price used in grade	None



D, the sloth

fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescan

split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: C/D from Aug 21, 2026, D from Oct 8, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats ("CRISPR") genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our genome-editing platform is based on our novel chRDNA (CRISPR hybrid RNA-DNA, or "chRDNA," pronounced "chardonnay") genome-editing technology, which enables more precise genome editing of allogeneic cell therapies.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 29.5						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(15.2%)	(6.6%)	29.5	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 58.1						
Twelve-month failure probability		0.42%	0.07%	81.0	248	2026-06-30
Altman Z double-prime		(9.88)	(0.31)	61.3	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		5.71x	2.96x	32.0	839	2025-12-31
Growth and financing, sleeve percentile 70.2						
Revenue growth, three-year compound		(7.0%)	10.0%	83.1	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		(22.3%)	2.1%	86.1	704	2025-12-31
Net share issuance, one year		3.9%	2.5%	41.5	634	2026-02-27


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.3 months

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
231	Strata Critical Medical, Inc. (SRTA)	62.2	C/D	short runway, fortress balance sheet
232	Embecta Corp. (EMBC)	62.4	C/D	late filer
233	Biogen Inc. (BIIB)	62.7	D	
234	Lenz Therapeutics, Inc. (LENZ)	63.0	D	short runway
235	AbbVie Inc. (ABBV)	63.2	D	
236	Caribou Biosciences, Inc. (CRBU) <	63.5	D	short runway
237	Royalty Pharma plc (RPRX)	63.8	D	
238	Integra Lifesciences Holdings Corp. (IART)	64.1	D	
239	Alpha Teknova, Inc. (TKNO)	64.3	D	
240	Arvinas, Inc. (ARVN)	64.6	D	short runway, fortress balance sheet
241	Organogenesis Holdings Inc. (ORGO)	64.9	D	fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(33.9%)	8.0%	22
Distance from 52-week high	(83.1%)	(31.4%)	7
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(217.8%)	(1.0%)	3
Book value to price	1.90	0.28	96
Sales to price	0.22	0.31	40
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.63)	(0.14)	22

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$26.2M

Operating cash flow, four quarters	-\$95.8M
Months of runway	3.3
Days since last periodic filing	57 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	\$1.7M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$148.1M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$111.0M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
3	assets	us-gaap:Assets	\$175.4M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
4	assets	us-gaap:Assets	\$313.3M	2024-12-31	2026-03-05	10-K	0001619856-26-000008
5	current assets	us-gaap:AssetsCurrent	\$145.2M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
6	current liabilities	us-gaap:LiabilitiesCurrent	\$25.4M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$596.5M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
8	operating income	us-gaap:OperatingIncomeLoss	-\$148.3M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
9	book equity	us-gaap:StockholdersEquity	\$122.2M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
10	liabilities	us-gaap:Liabilities	\$53.2M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
11	operating income	us-gaap:OperatingIncomeLoss	-\$67.0M	2021-12-31	2023-03-09	10-K	0001619856-23-000037
12	interest expense	us-gaap:InterestExpense	\$8,000	2021-12-31	2022-03-21	10-K	0000950170-22-004233
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$11.2M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$10.0M	2024-12-31	2026-03-05	10-K	0001619856-26-000008
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$34.5M	2023-12-31	2025-03-10	10-K	0001619856-25-000015
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$13.9M	2022-12-31	2024-03-11	10-K	0001619856-24-000013
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.4M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$138.2M	2024-12-31	2026-03-05	10-K	0001619856-26-000008
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.9M	2024-12-31	2026-03-05	10-K	0001619856-26-000008
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$93.3M	2023-12-31	2025-03-10	10-K	0001619856-25-000015
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$11.6M	2023-12-31	2025-03-10	10-K	0001619856-25-000015
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$91.0M	2022-12-31	2024-03-11	10-K	0001619856-24-000013
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$6.5M	2022-12-31	2024-03-11	10-K	0001619856-24-000013
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$3.6M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$148.7M	2025-12-31	2026-03-05	10-K	0001619856-26-000008
26	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$550,000	2025-12-31	2026-03-05	10-K	0001619856-26-000008
27	current assets	us-gaap:AssetsCurrent	\$219.4M	2024-12-31	2026-03-05	10-K	0001619856-26-000008
28	current liabilities	us-gaap:LiabilitiesCurrent	\$30.7M	2024-12-31	2026-03-05	10-K	0001619856-26-000008
29	assets	us-gaap:Assets	\$432.2M	2023-12-31	2025-03-10	10-K	0001619856-25-000015
30	assets	us-gaap:Assets	\$373.8M	2022-12-31	2024-03-11	10-K	0001619856-24-000013
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	96,637,202	2026-02-27	2026-03-05	10-K	0001619856-26-000008
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	93,004,602	2025-03-04	2025-03-10	10-K	0001619856-25-000015